A practical reference on Lipodystrophy: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-18 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
A common substrate used in this type of system is glass. Depending if the system is open or closed, there would be either one or two layers of glass. The bottom layer of the device contains a patterned array of individually controllable electrodes. When looking at a closed system, there is usually a continuous ground electrode found through the top layer made usually of indium tin oxide (ITO). The dielectric layer is found around the electrodes in the bottom layer of the device and is important for building up charges and electrical field gradients on the device. A hydrophobic layer is applied to the top layer of the system to decrease the surface energy where the droplet will actually be in contact with. The applied voltage activates the electrodes and allows changes in the wettability of droplet on the device's surface. In order to move a droplet, a control voltage is applied to an electrode adjacent to the droplet, and at the same time, the electrode just under the droplet is deactivated. By varying the electric potential along a linear array of electrodes, electrowetting can be used to move droplets along this line of electrodes. Modifications to this foundation can also be fabricated into the basic design structure. One example of this is the addition of electrochemiluminescence detectors within the indium tin oxide layer (the ground electrode in a closed system) which aid in the detection of luminophores in droplets. In general, different materials may also be used to replace basic components of a DMF system such as the use of PDMS instead of glass for the substrate.
An ACS program chair, Gopal Coimbatore, said that without a proper forum the matter would never be discussed and, "with the world facing an energy crisis, it is worth exploring all possibilities." On 22–25 March 2009, the American Chemical Society meeting included a four-day symposium in conjunction with the 20th anniversary of the announcement of cold fusion. Researchers working at the U.S. Navy's Space and Naval Warfare Systems Center (SPAWAR) reported detection of energetic neutrons using a heavy water electrolysis setup and a CR-39 detector, a result previously published in Naturwissenschaften. The authors claim that these neutrons are indicative of nuclear reactions. Without quantitative analysis of the number, energy, and timing of the neutrons and exclusion of other potential sources, this interpretation is unlikely to find acceptance by the wider scientific community.
=== Marketing === The motion poster of Darbar was released on 7 November 2019. Kamal Haasan, Salman Khan, Mohanlal and Mahesh Babu released the film's posters. The film's trailer was released at a launch event in Mumbai on 16 December, with Rajinikanth, Suniel Shetty and Murugadoss in attendance. To make the film's promotion unique, the filmmakers wrapped a SpiceJet aeroplane with Darbar Rajini livery. The external branding of the aircraft bore an image of Rajinikanth in police uniform. Speaking to The Hindu, R. Kannan, chief operating officer (COO) of Lyca Productions said, "The film will release in 7,000 screens across the world. We are planning to release it in a few islands to reach out to the maximum number of people". He said around ₹70–80 million was being spent on promoting the film, calling the marketing investment "one of the highest in Tamil cinema". Kannan said around 15 brands such as SpiceJet, Cadbury's, BookMyShow and Airtel had marketing deals with the film.
Sources: en.wikipedia.org
==== Absorption ==== Following a single oral dose of sertraline, mean peak blood levels of sertraline occur between 4.5 and 8.4 hours. Bioavailability is likely linear and dose-proportional over a dose range of 150 to 200 mg. Concomitant intake of sertraline with food slightly increases sertraline peak levels and total exposure. There is an approximate 2-fold accumulation of sertraline with continuous administration and steady-state levels are reached within one week.
== History == In 1935, Hans Adolf Krebs discovered D-amino acid oxidase after an experiment with porcine kidney homogenates and amino acids. Shortly after, Warburg and Christian observed the oxidase had a FAD cofactor making it the second flavoenzyme to be discovered. In the upcoming years other scientists developed and improved the purification procedure for a porcine D-amino acid oxidase. In 1983, inhibitors for the oxidase were discovered. In 2006, the 3D structure of the oxidase was published. Currently, the link between human D-amino acid oxidase (hDAAO) activity and schizophrenia is being researched.
== Commercial activities == Borchers co-founded MRM Proteomics Inc. in 2010 as a spin-off commercializing proteomics technology developed at the University of Victoria–Genome BC Proteomics Centre. He serves as a scientific advisor to the company and chairs its board of directors. MRM Proteomics commercializes targeted proteomics assay kits, marketed under the name PeptiQuant, applying the MRM-based quantitation methods developed in Borchers' academic laboratories, and is developing kits based on the SysQuan method. The company has since built a series of industry partnerships around this technology: it granted the lung cancer diagnostics firm Biodesix rights to use its iMALDI technology in blood-based diagnostic test development in 2018, and entered a co-marketing agreement with Agilent Technologies in 2022 to develop targeted proteomics assay kits for Agilent's mass spectrometry platforms. In 2023, a project led by Borchers with MRM Proteomics received $3.03 million through Genome Canada's Genomic Applications Partnership Program to develop "MutaQuant" mass spectrometry kits measuring the protein-level impact of around 1,000 known cancer mutations, to be commercialized by MRM Proteomics and Agilent. In addition to MRM Proteomics, Borchers co-founded Molecular You, a Vancouver-based company offering blood-based multi-omic health assessments, where he serves as chief lab analytics officer, and Creative Molecules, Inc.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.